Paper Spotlight: Sharing R&D Risk in Healthcare via FDA Hedges
Recent estimates suggest that the cost of developing a single new drug in the biopharmaceutical sector is $2.6 billion, confirming the very large amounts of money that medical companies invest to develop a new treatment. Biomedical companies also face the risk of very low rates of success, not only due to the inherent scientific risk of developing… Read More »Paper Spotlight: Sharing R&D Risk in Healthcare via FDA Hedges